Navitus’ growth, transparency, and
superb customer service were featured in a recent edition of Insight on Business magazine.
“Word-of-mouth about our transparency as well as great customer service are leading to the growth,” said Navitus President & CEO Terry Seligman.
Read more about Navitus, including client testimonials, in the article "Elixir for Growth: Navitus embraces transparency to dramatically reduce drug costs."
Hospira, Inc., a Pfizer company, recalled 8.4% Sodium Bicarbonate Injection USP. These products came from lot 56-148-EV, expiring August 1, 2017.
Teva Pharmaceuticals voluntarily recalled amikacin sulfate injection USP, 1 gram/4mL (250 mg/mL) vials from lot 4750915. This drug is used in the short term to treat severe infections.
Contact Us | Careers | MedicareRx (PDP) | Navi-Gate Rx | Site Map | Confidentiality Statement | Vendor/FDR
Download Adobe Reader